Co-mutation Patterns of TP53, KRAS, EGFR, STK11 and KEAP1 in Lung Adenocarcinoma: TCGA-LUAD Analysis and Descriptive Comparison with AACR Project GENIE: Five-gene mutation status, exact pairwise tests, and descriptive external comparison
Abstract
Background: LUAD is a lung cancer that demonstrates various mutations, both cancer-promoting (oncogenic) and cancer-suppressing (tumor-suppressor) processes. This study aimed to assess co-occurrence of TP53, KRAS, EGFR, STK11 and KEAP1 mutations by scanning TCGA-LUAD and correlate the resulting frequencies with the corresponding data from AACR Project GENIE. Methods: PanCancer Atlas mutation export for TCGA-LUAD comprising 503 samples in total was analyzed and obtained the mutation frequency counts with the subsequent calculations of the respective 95% Wilson confidence intervals and the associations (9 pairs of genes) verified through bidirectional Fisher's exact test with Benjamini-Hochberg FDR and Bonferroni correction. In TCGA-LUAD, mutation-positive rates were as follows: TP53 51.9%, KRAS 30.6%, KEAP1 18.5%, STK11 14.5% and EGFR 12.9%. Eight of the ten gene-pair associations achieved FDR q<0.05, with six remaining significant under Bonferroni correction. The association between KRAS and EGFR was negative (OR 0.029; 95% CI 0.001–0.172), while associations between KRAS and STK11 (OR 2.567; 95% CI 1.499–4.397) and between STK11 and KEAP1 (OR 2.766; 95% CI 1.526–4.936) were positive. The key hotspot patterns in KRAS and EGFR appeared qualitatively similar in the GENIE dataset for NSCLC. Conclusion: TCGA-LUAD presented dependencies between these five genes that were non-random, with GENIE data being non-inferential.
Keywords: lung adenocarcinoma; TCGA-LUAD; cBioPortal; AACR Project GENIE; TP53; KRAS; EGFR; STK11; KEAP1; co-mutation; mutual exclusivity.